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Introduction 
The randomized double-blind controlled clinical trial (RCT) is the undisputed gold-standard 
for assessing drug efficacy. However the RCT is usually insufficiently powered, or too brief, 
to detect rare but serious adverse effects or modest but important increases in the risk of 
common disease outcomes (such as coronary heart disease events) that can have a major 
population impact in absolute terms. Pooling individual trials via meta-analyses sometimes 
helps but the reporting of information on adverse effects in clinical trials is often incomplete 
or poorly quantified, particularly when compared to the efficacy endpoints. Clinically 
significant and unexpected abnormal laboratory values may not be detected as not all are 
routinely included in trial protocols. Most RCTs also tend to exclude the elderly, patients with 
co-morbidity or pregnancy, and this reduces the generalisability of these data. Therefore, at 
the time of product launch, there are often limited safety data of any new drug, in both the 
short- and longer-term which is directly applicable to that of the target population. Drugs in 
use therefore need to remain under constant surveillance (pharmacovigilance) and study by 
observation (pharmacoepidemiology)  Pharmacovigilance systems identify safety signals 
(signal detection) and thus serve to generate hypothesis. Pharmacoepidemiology tests such 
hypothesis (signal validation) and quantifies the risk. Both pharmacovigilance and 
pharmacoepidemiology have limitations, are complementary and only partially overlap.  
 
What is the problem? 
Current pharmacovigilance systems rely heavily on spontaneous case reports. Although there 
have been some notable successes, this system has deficiencies. First, the onus on reporting is 
placed on patients (in some countries only such as the US and UK) and on already busy health 
professionals so under-reporting is likely. Several studies have shown that some adverse 
effects are more likely to be under-reported for a variety of other reasons.
1
 Second, the system 
is better placed to detect rare and unusual adverse effects (such as tendon rupture from 
ciprofloxacin), than for the detection of modest increases in the risk of more common clinical 
outcomes already prevalent in the patient groups being treated (such as myocardial infarction 
in patients with diabetes and obesity receiving new therapies for these conditions). Third, 
such case reports lack appropriate denominator information and therefore cannot be 
effectively used to estimate the likely incidence. Fourth, analysis of spontaneous reporting 
may be influenced by external factors such as media interest or safety alerts (notoriety bias). 
Fifth, there is also the requirement for the reporter to make a [possible] link between the drug 
and an event 
 
Concerns about possible adverse effects often prompt cohort studies where the risk of the 
suspected adverse effect is compared among those exposed and unexposed to the drug in 
question. These can be effective, but this design is limited by the non-randomized exposure to 
the drug so that exposed and unexposed groups can differ systematically in the risk of the 
adverse effect in question. These systematic differences can confound interpretation of the 
causal relationship between [drug] exposure and [adverse] outcome which can be both 
difficult to measure and/or control for. One potentially important source of confounding 
relates to the decision to prescribe a new drug or not (confounding by indication). If, for 
example, the adverse effect is already suspected, doctors may be less likely to prescribe the 
drug in question to those at higher risk and a cohort study may thus bias the estimate of the 
risk of the adverse effect towards the null. Alternatively, a drug could be [incorrectly] 
considered to be safer and clinicians may be more likely to select higher risk patients for 
treatment which would thus inflate the overall risk estimate. Case-control studies are another 
alternative where the exposure status is compared in patients with the outcome of interest 
versus patients without. The case-control approach is more effective at identifying relatively 
newly suspected adverse effects when the adverse effect being studied is otherwise rare in the 
group being treated (such as phocomelia from thalidomide exposure). Case-control studies are 
relatively rapid and inexpensive to conduct as compared to cohort studies, however, also 
suffer from recall bias and face difficulties in selection of appropriate controls.   
Can some of these limitations be overcome? 
Is there an alternative way of reliably evaluating modest increases in the risk of common 
adverse effects using routinely collected clinical data? The self-controlled case series method 
developed by Farrington
2
 and described by Whitaker
3
 was designed to assess the association 
between a time-varying exposure and an outcome event and was originally applied to adverse 
effects of vaccines. More recently, we have applied this method to the investigation of drug 
safety using information on drug prescription and clinical diagnoses from the UK General 
Practice Research Database (GPRD);
4-6
 although other sources capturing clinical and 
exposure data can be used (e.g. The Health Improvement Network [THIN] or health insurance 
databases). Figure 1 provides a pictorial representation of the self-controlled case series safety 
analysis of drugs.  Briefly, the method involves comparison of events occurring in pre-defined 
intervals during exposure relative to all other observed time [baseline period] for a sampled 
individual. 
 
This method is advantageous as it only requires assessment of cases and it eliminates fixed 
confounders as the comparisons are intra-person. This technique will thus remove variation 
between individuals in risk factors for the disease outcome of interest. Hence, fixed 
confounders (e.g. gender, socioeconomic class) are implicitly controlled for which overcomes 
many of the issues encountered with traditional inter-person designs. Age or temporal 
variation can also be accounted for and under certain circumstances it retains high relative 
efficiency.
7
 
 
The single most important limitation of the self-controlled case-series method is the 
requirement that events do not affect subsequent exposures;
8
 this limits the utility of the 
method in assessing already well-known adverse effects Confounding can also occur with 
factors that change within an individual over time and which are independently associated 
with both exposure and outcome. Such time-varying confounders could considerably bias a 
self-controlled case-series analysis and would need to be identified and factored into any 
study design. For example, the decision to prescribe inhaled anti-cholinergics may be 
associated with periods of chronic obstructive pulmonary disease exacerbation, and such 
periods may be independently associated with an increased risk of the outcome under 
investigation (e.g. stroke). Recognition of potential time-varying confounders and sensitivity 
analysis excluding individuals in whom this is a possibility is integral to the approach.   
Another potential source of bias is death due to the adverse effect ending an observation 
earlier than it would have otherwise; as the self-controlled case-series method requires the 
assumption that the occurrence of an event does not censor, or affect, the observation period.
8
 
Such bias is difficult to quantify and could be in either direction. Also as timing is crucial in a 
self-controlled case-series evaluation one has to pay particular attention to any factor that may 
introduce error; this makes studies of late-onset effects more difficult. In addition, this method 
is not easily amenable to a significant proportion of chronic therapies, such as those requiring 
lifelong administration without change or interruption e.g. subcutaneous insulin in Type I 
diabetes. In addition, the method will only work when the event risk is small over the 
observation period.
3
 Moreover, the method requires variability in the time [or age] of the 
event.
8
 The self-controlled case-series technique is also only able to provide an estimate of the 
relative, and not more clinically relevant, absolute incidence [though external measures could 
be used and the self-controlled case-series generated rate ratio applied].  
 
What is the future? 
Improvements to post-marketing drug safety assessment are already occurring through 
innovations and advances in data mining, signal detection and signal validation methodology. 
Moreover other electronic monitoring systems are increasingly being combined with other 
electronic database sources which allow for further large-scale drug safety monitoring. 
An example is the EU-ADR computerized system which has recently being developed for 
signal detection that exploits clinical data across Europe. Researchers then apply a variety of 
text mining, epidemiological and computational techniques.  
 
Interpretation of results from different methods for evaluation of drug safety should not be 
viewed in isolation because each approach is complementary as each method has differing 
aims, strengths and weaknesses. Indeed, clearer insight may be gained by comparing, where 
possible, the results from each type of analysis using principles recently outlined for 
understanding the causal relevance of biomarkers for disease risk.
9
 Importantly, the efficiency 
and versatility of the self-controlled case-series method suggest that [when correctly applied 
and conducted] this technique could develop as an important adjunct in drug safety 
assessment.  
 
Post-marketing observational studies currently remain unregistered and can be analysed in 
myriad ways.
10
 Indeed, there is no way of knowing how many analyses are attempted before a 
particular result is reported Although regulatory authorities have increasingly required 
commitments to conduct post-marketing studies as a condition of approval, many of these 
commitments remain unmet.
11
 Most new drugs will subsequently require safety labelling 
changes as experience grows and new information emerges. For example, one in ten drugs are 
ultimately withdrawn or become retrospectively subject to warnings about serious or life-
threatening adverse effects.
12
 We believe the evidence used in making these decisions could 
be further improved; a recent report showed most decisions to remove a drug from the market 
are based on data from animal studies and spontaneous reports rather than formal clinical 
studies.
13
 However as most pharmacoepidemiological studies require time, rescource and 
expertise, they may not always be considered necessary when the risk is considered high and 
safer alternatives are readily available. Utilisation of controlled case-only techniques (such as 
the self-controlled case series method) may facilitate an increase in the number of analyses 
that can be undertaken independently of the drug manufacturers. Finally, we also suggest that 
studies in relation to drug assessment should now all be registered in the same way as clinical 
trials. 
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Figure 1: Pictorial representation of a self-controlled case series method where age-adjusted incidence 
rate ratios of the outcome of interest are derived using Conditional Poisson Regression by comparing 
defined intervals during the exposure period relative to all other observed time [baseline period] for each 
person.  
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